<DOC>
	<DOCNO>NCT00992901</DOCNO>
	<brief_summary>RYGB ( roux-en-y gastric bypass ) report reverse type 2 diabetes ( T2DM ) immediately surgery significant weight loss . In addition , grow number patient recognize life-threatening hyperinsulinemic hypoglycemia several year follow surgery . While mechanisms RYGB improve glucose metabolism alters islet cell function patient RYGB understood , recent study suggest increase secretion GI hormone , primarily glucagon-like peptide 1 ( GLP-1 ) , well alteration neural activity may contribute enhanced insulin secretion general , great extent patient hypoglycemia . The propose research design address role RYGB insulin secretion evaluate contribution stimulatory factor ( neural GI hormone ) islet cell function islet cell responsiveness physiologic stimulatory factor , RYGB patient without hypoglycemia non-operated control .</brief_summary>
	<brief_title>Role Neural Hormonal Regulation Factors Insulin Secretion After Gastric Bypass Surgery</brief_title>
	<detailed_description>RYGB ( roux-en-y gastric bypass ) report reverse type 2 diabetes ( T2DM ) immediately surgery significant weight loss . In addition , grow number patient recognize life-threatening hyperinsulinemic hypoglycemia several year follow surgery . While mechanisms RYGB improve glucose metabolism alters islet cell function patient RYGB understood , recent study suggest increase secretion GI hormone , primarily glucagon-like peptide 1 ( GLP-1 ) , well alteration neural activity may contribute enhanced insulin secretion general , great extent patient hypoglycemia . The propose research design address role RYGB insulin secretion evaluate contribution stimulatory factor ( neural GI hormone ) islet cell function islet cell responsiveness physiologic stimulatory factor , RYGB patient without hypoglycemia non-operated control</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<criteria>Hypoglycemic RYGB patient document blood glucose level &lt; 50 mg/dl Asymptomatic individual bariatric surgery Healthy nonsurgical patient personal history diabetes Subjects must physically able come clinical research center CedarsSinai Medical Center Active heart , lung , liver , gastrointestinal kidney disease ; unable give inform consent ; pregnancy ; uncontrolled high blood pressure high cholesterol ; significant anemia ( hemoglobin &lt; 11g/dL ) ; prisoner institutionalize individual ; type 2 diabetes melitis ; development serious medical psychiatric illness recruitment study ; RYGB patient also disqualify gastric outlet obstruction severe diarrhea Healthy nonsurgical patient personal history diabetes For administration atropine , follow exclusion also apply : History glaucoma Uncontrolled hypertension ( subject BP &gt; 140/90 history dyslipidemia Taking medication might interact atropine stop exclude study ) Myasthenia gravis Brain pathology Enlarged prostate men</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>gastric bypass surgery</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>Insulin response meal ingestion</keyword>
	<keyword>Gut hormone neural response meal ingestion</keyword>
</DOC>